Cite
HARVARD Citation
Gong, J. et al. (n.d.). 339 Preliminary safety, tolerability and efficacy results of KN026 (a HER2-targeted Bispecific Antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in patients (pts) with HER2 aberrated solid tumors. Journal for immunotherapy of cancer. p. A207. [Online].